Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beta Bionics, Inc.BBNX · Entity 2350 | Director | May 21, 2026 | May 26, 2026 |
| Lyra Therapeutics, Inc.LYRA · Entity 46837 | Director · Principal Executive Officer | April 01, 2026 | April 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beta Bionics, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 29,397 |
Reported balance
After 2026-05-21 transaction · row 1
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 16,965 · Balance 29,397 F1: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan.
Lyra Therapeutics, Inc.
Report date April 01, 2026 · Filed April 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,094,733 |
Reported balance
After 2026-04-01 transaction · row 1
1 source rowRow 1 · 2026-04-01 · Disposition to issuer · Disposed 2,000 · Balance 1,094,733 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 21, 2026 Filed May 26, 2026 22:00 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantCommon Stock | 16,965 | $0.00 | $0.00 |
DisclosureSEC source: 0001810701-26-000003 · form4-05262026_060528.xml · nonDerivative · entry 1 Palasis Maria · CIK 0001810701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,397 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. Read SEC document |
| April 01, 2026 Filed Apr 3, 2026 20:05 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | Disposition to issuerCommon Stock | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-142100 · ownership.xml · nonDerivative · entry 1 Palasis Maria · CIK 0001810701 · Director · Principal Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,094,733 Read SEC document |
| January 13, 2026 Filed Jan 15, 2026 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantCommon Stock | 3,997 | $0.00 | $0.00 |
DisclosureSEC source: 0001810701-26-000002 · form4-01142026_080107.xml · nonDerivative · entry 1 Palasis Maria · CIK 0001810701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,432 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. Read SEC document |
| January 06, 2026 Filed Jan 8, 2026 21:30 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | SaleCommon Stock | 1,702 | $3.36 | $5,725.53 |
DisclosureSEC source: 0001193125-26-007751 · ownership.xml · nonDerivative · entry 1 Palasis Maria · CIK 0001810701 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,096,733 F1 · kind: Shares were sold to cover taxes upon the vesting of restricted stock units ("RSUs") pursuant to a mandatory Rule 10b5-1 trading instruction in the award agreement adopted by the Reporting Person on January 1, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 21:20 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 500 | $29.96 | $14,982.00 |
DisclosureSEC source: 0001810701-25-000007 · form4-12022025_041202.xml · nonDerivative · entry 2 Palasis Maria · CIK 0001810701 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,435 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025. F3 · price: The weighted average sale price for the transaction reported was $29.9640 and the range of prices were between $29.80 and $30.23. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| December 01, 2025 Filed Dec 2, 2025 21:20 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 906 | $29.33 | $26,570.17 |
DisclosureSEC source: 0001810701-25-000007 · form4-12022025_041202.xml · nonDerivative · entry 1 Palasis Maria · CIK 0001810701 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 8,935 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025. F2 · price: The weighted average sale price for the transaction reported was $29.3269 and the range of prices were between $28.75 and $29.63. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 31, 2025 Filed Nov 6, 2025 02:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 119 | $27.45 | $3,266.57 |
DisclosureSEC source: 0001810701-25-000005 · form4-11052025_091101.xml · nonDerivative · entry 2 Palasis Maria · CIK 0001810701 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,841 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025. F3 · price: The weighted average sale price for the transaction reported was $27.4502 and the range of prices were between $27.32 and $27.57. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 31, 2025 Filed Nov 6, 2025 02:45 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | SaleCommon Stock | 1,287 | $26.86 | $34,567.28 |
DisclosureSEC source: 0001810701-25-000005 · form4-11052025_091101.xml · nonDerivative · entry 1 Palasis Maria · CIK 0001810701 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,960 F1 · kind: Represents shares sold pursuant to a Rule 10b5-1 Plan adopted on July 31, 2025. F2 · price: The weighted average sale price for the transaction reported was $26.8588 and the range of prices were between $26.27 and $27.22. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:15 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantEmployee Stock Option (right to buy) · Derivative | 3,667 | $0.00 Strike: $303.50 | $0.00 |
DisclosureSEC source: 0001193125-25-230193 · ownership.xml · derivative · entry 1 Palasis Maria · CIK 0001810701 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,333 Underlying: Common Stock · 3,667 shares Expires 2034-03-20 F1 · derivative.exercise_date: On March 21, 2024, the Reporting Person was granted a performance stock option ("PSO") for an aggregate of up to 11,000 shares of common stock (or 550,000 shares on a pre-split basis) under the Issuer's 2020 Incentive Award Plan (the "Agreement"). Under the terms of the Agreement, the underlying PSO shares will vest upon certain milestone events. On October 1, 2025, the Issuer determined that Milestone 2 of the PSO was achieved, resulting in 3,667 PSOs being earned. The earned PSOs will vest on January 31, 2028. Read SEC document |
| July 10, 2025 Filed Jul 15, 2025 01:27 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | SaleCommon Stock | 1,565 | $8.91 | $13,944.15 |
DisclosureSEC source: 0000950170-25-095682 · ownership.xml · nonDerivative · entry 1 Palasis Maria · CIK 0001810701 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,098,435 F1 · kind: Shares were sold to cover taxes upon the vesting of restricted stock units ("RSUs") pursuant to a mandatory Rule 10b5-1 trading instruction in the award agreement adopted by the Reporting Person on January 1, 2025 in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended. Read SEC document |
| March 15, 2025 Filed Mar 19, 2025 00:00 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantCommon Stock | 11,247 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008536 · form4-03182025_080308.xml · nonDerivative · entry 1 Palasis Maria · CIK 0001810701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,247 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2025 Equity Incentive Plan. Read SEC document |
| January 31, 2025 Filed Feb 4, 2025 01:30 UTC | Beta Bionics, Inc. BBNX · Entity 2350 | GrantDirector Stock Option (right to buy) · Derivative | 9,137 | $0.00 Strike: $7.51 | $0.00 |
DisclosureSEC source: 0001415889-25-002821 · form4-02032025_080215.xml · derivative · entry 1 Palasis Maria · CIK 0001810701 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,137 Underlying: Common Stock · 9,137 shares Expires 2033-01-24 F1 · derivative.exercise_date: The shares subject to this option shall vest in 36 equal monthly installments measured from August 15, 2022. F2 · derivative.underlying: Immediately prior to the closing of the initial public offering, each share of Class B Common Stock subject to this option was converted into an equal number of shares of Common Stock. Read SEC document |
| January 08, 2025 Filed Jan 10, 2025 21:15 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantCommon Stock | 800,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-004167 · ownership.xml · nonDerivative · entry 1 Palasis Maria · CIK 0001810701 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,100,000 F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in three substantially equal installments occurring on July 1, 2025, January 1, 2026 and July 1, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| December 09, 2024 Filed Dec 11, 2024 23:54 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantEmployee Stock Option (right to buy) · Derivative | 183,333 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0000950170-24-135537 · ownership.xml · derivative · entry 1 Palasis Maria · CIK 0001810701 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 183,333 Underlying: Common Stock · 183,333 shares Expires 2034-03-20 F1 · derivative.exercise_date: On March 21, 2024, the Reporting Person was granted a performance stock option ("PSO") for an aggregate of up to 550,000 shares of common stock under the Issuer's 2020 Incentive Award Plan (the "Agreement"). Under the terms of the Agreement, the underlying PSO shares will vest upon certain milestone events. On December 9, 2024, the Issuer determined that Milestone 1 of the PSO was achieved, resulting in 183,333 PSOs being earned. The earned PSOs will vest on January 31, 2028. Read SEC document |
| October 16, 2024 Filed Oct 18, 2024 20:05 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantCommon Stock | 300,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-115597 · ownership.xml · nonDerivative · entry 1 Palasis Maria · CIK 0001810701 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 F1 · shares: Represents an award of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of the Issuer's common stock. The RSUs will vest in three substantially equal installments occurring on April 1, 2025, October 1, 2025 and April 1, 2026, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date. Read SEC document |
| March 18, 2024 Filed Mar 20, 2024 23:20 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 500,000 | $0.00 Strike: $5.77 | $0.00 |
DisclosureSEC source: 0000950170-24-034348 · ownership.xml · derivative · entry 1 Palasis Maria · CIK 0001810701 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 500,000 Underlying: Common Stock · 500,000 shares Expires 2034-03-17 F1 · derivative.exercise_date: This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 31, 2024. Read SEC document |
| June 15, 2023 Filed Jun 26, 2023 21:39 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 150,000 | $0.00 Strike: $2.99 | $0.00 |
DisclosureSEC source: 0000950170-23-029918 · ownership.xml · derivative · entry 1 Palasis Maria · CIK 0001810701 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2023-06-14 F1 · derivative.exercise_date: This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following June 15, 2023. Read SEC document |
| June 15, 2023 Filed Jul 12, 2023 22:36 UTC Amendment | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 150,000 | $0.00 Strike: $2.99 | $0.00 |
DisclosureSEC source: 0000950170-23-032707 · ownership.xml · derivative · entry 1 Palasis Maria · CIK 0001810701 · Director · President & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2033-06-14 F1 · derivative.exercise_date: This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following June 15, 2023. F2 · derivative.expiration_date: This Form 4 amendment is being filed to correct the expiration date of the stock option granted to the Reporting Person. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 22:09 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 250,000 | $0.00 Strike: $2.85 | $0.00 |
DisclosureSEC source: 0000899243-23-003510 · doc4.xml · derivative · entry 1 Palasis Maria · CIK 0001810701 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2033-01-30 F1 · derivative.exercise_date: This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following January 31, 2023. Read SEC document |
| February 16, 2022 Filed Feb 18, 2022 22:12 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 175,000 | $0.00 Strike: $4.21 | $0.00 |
DisclosureSEC source: 0000899243-22-007042 · doc4.xml · derivative · entry 1 Palasis Maria · CIK 0001810701 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2032-02-15 F1 · derivative.exercise_date: On February 16, 2022, the Reporting Person was granted an option to purchase 175,000 shares of common stock. The option vests and becomes exercisable as to 58,333 shares underlying the option when the Issuer's market capitalization reaches $250,000,000; (ii) 58,333 shares underlying the option when the Issuer's market capitalization reaches $350,000,000; and (iii) 58,334 shares underlying the option when the Issuer's market capitalization reaches $500,000,000, all subject to the Reporting Person's continued service to the Issuer through each such date. Read SEC document |
| February 12, 2022 Filed Feb 16, 2022 02:31 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 127,400 | $0.00 Strike: $4.78 | $0.00 |
DisclosureSEC source: 0000899243-22-006546 · doc4.xml · derivative · entry 1 Palasis Maria · CIK 0001810701 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,400 Underlying: Common Stock · 127,400 shares Expires 2032-02-11 F1 · derivative.exercise_date: This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following February 12, 2022. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 21:05 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 120,000 | $0.00 Strike: $10.63 | $0.00 |
DisclosureSEC source: 0000899243-21-005656 · doc4.xml · derivative · entry 1 Palasis Maria · CIK 0001810701 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2031-02-07 F1 · derivative.exercise_date: This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following February 8, 2021. Read SEC document |
| April 30, 2020 Filed May 1, 2020 22:36 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 326,303 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-20-011749 · doc4.xml · derivative · entry 1 Palasis Maria · CIK 0001810701 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 326,303 Underlying: Common Stock · 326,303 shares Expires 2030-04-29 F1 · derivative.exercise_date: This option vests and becomes exercisable in 48 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following April 30, 2020. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.